Last quarter (Q4 2023), Verona Pharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Verona Pharma's net income was $-14.13M. See Verona Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 18
Total Revenue	-	-	$ 458.00K	$ 40.00M	$ 0.00	$ 0.00
Cost of Revenue	-	-	$ 346.00K	-	-	-
Gross Profit	-	-	$ 112.00K	$ 40.00M	-	-
Operating Expense	$ 67.57M	$ 67.57M	$ 75.86M	$ -113.31M	$ 66.01M	$ 32.48M
Operating Income	$ -72.52M	$ -67.57M	$ -75.75M	$ -73.31M	$ -66.01M	$ -32.48M
Net Non Operating Interest Income Expense	$ 7.27M	$ -2.06M	$ -521.00K	$ 17.55M	$ 86.00K	$ 958.02K
Other Income Expense	$ -4.54M	$ -13.87M	$ -11.64M	$ 2.25M	$ 924.00K	-
Pretax Income	$ -53.90M	$ -53.90M	$ -68.45M	$ -55.59M	$ -65.00M	$ -30.62M
Tax Provision	$ 474.00K	$ 474.00K	$ 253.00K	$ -18.00K	$ 146.00K	$ -5.37M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -48.45M	$ -54.37M	$ -68.70M	$ -55.57M	$ -65.15M	$ -25.25M
Basic EPS	$ -0.08	$ -0.09	$ -0.13	$ -0.12	$ -2.00	-
Diluted EPS	$ -0.08	$ -0.09	$ -0.13	$ -0.12	$ -2.00	-
Basic Average Shares	$ 2.54B	$ 634.14M	$ 529.07M	$ 473.19M	$ 32.87M	-
Diluted Average Shares	$ 2.54B	$ 634.14M	$ 529.07M	$ 473.19M	$ 32.87M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	$ 1.60	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	$ 487.26K
Total Expenses	$ 67.57M	$ 67.57M	$ -76.21M	$ -113.31M	$ 66.01M	$ 32.48M
Net Income From Continuing And Discontinued Operation	$ -54.37M	$ -54.37M	$ -68.70M	$ -55.57M	$ -65.15M	$ -25.25M
Normalized Income	$ -32.52M	$ -42.58M	-	-	$ -65.89M	$ -23.98M
Interest Expense	-	-	-	-	$ 35.00K	$ 0.00
EBIT	$ -51.84M	$ -51.84M	$ -67.93M	$ -55.25M	$ -64.97M	$ -30.62M
EBITDA	$ -50.94M	$ -50.94M	$ -67.10M	$ -54.38M	$ -64.34M	$ -30.50M

Currency in USD

Verona Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing